Regeneron Pharmaceuticals (REGN) Change in Receivables (2009 - 2026)

Regeneron Pharmaceuticals' Change in Receivables history runs 18 years deep, the most recent figure standing at -$1.2 million for Q1 2026.

• In Q1 2026, Change in Receivables rose 99.82% year-over-year to -$1.2 million; the TTM figure through Mar 2026 stood at $158.5 million (down 53.79% YoY), while the FY2025 annual figure was -$498.1 million, down 189.91% from the prior year.
• Change in Receivables was -$1.2 million for Q1 2026 at Regeneron Pharmaceuticals, down from $51.2 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $494.1 million in Q2 2024 to a low of -$1.2 billion in Q1 2022.
• Historically, Change in Receivables has averaged -$18.5 million across 5 years, with a median of $51.2 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Change in Receivables sank 2154.03% in 2022, then jumped 18200.0% in 2024.
• A 5-year view of Change in Receivables shows it stood at -$219.6 million in 2022, then soared by 137.66% to $82.7 million in 2023, then jumped by 42.44% to $117.8 million in 2024, then sank by 56.54% to $51.2 million in 2025, then slumped by 102.34% to -$1.2 million in 2026.
• The last three Change in Receivables figures came in at -$1.2 million (Q1 2026), $51.2 million (Q4 2025), and $80.3 million (Q3 2025), per Business Quant data.